INS and Hypoglycemia: Significantly, the expert opinion of 97.1% of respondents was that CGM devices should be reimbursed for any person with T2D on any insulin therapy, and 34.3% indicated that CGM should be prescribed for any person with T2D at risk of hypoglycaemia on any therapy (Table S7), whether insulin or non‐insulin.